Better Buy: Amgen vs. Bristol Myers Squibb

Amgen (NASDAQ: AMGN) owes a debt of thanks to Bristol Myers Squibb (NYSE: BMY). For BMS to completed its acquisition of Celgene last year, regulators required that Celgene first sell immunology drug Otezla. Amgen was more than happy to shell out $13.4 billion for the blockbuster drug.

After gobbling up Celgene, BMS' market cap jumped significantly and now rivals that of Amgen. The companies could also compete against each other in several indications if some of their pipeline candidates are successful in clinical testing. 

Which of these stocks is the better pick for long-term investors now? Here's how Amgen and BMS compare in key categories.

Continue reading

Source Fool.com